Burzynski Research Institute (BZYR) Cash from Operations (2010 - 2025)
Burzynski Research Institute (BZYR) posted Cash from Operations of 823106.0 for Q4 2025, down 767.28% sequentially from 94907.0 in Q3 2025, and up 7.54% YoY from 765361.41 in Q4 2024.
Burzynski Research Institute (BZYR) Cash from Operations (2010 - 2025) Analysis & Trends
Burzynski Research Institute has reported Cash from Operations for 16 years, with the latest figure at 823106.0 in Q4 2025.
- Quarterly Cash from Operations rose 7.54% year-over-year to 823106.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was 257784.0 (up 79.14% YoY) and the FY2025 annual result came in at 388531.0, up 25.82% from the prior year.
- Cash from Operations slipped to 823106.0 in Q4 2025 per BZYR's latest filing, from 94907.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 709372.0 in Q1 2025 and troughed at 890275.0 in Q4 2024.
- A 5-year average of 125190.25 and a median of 85921.0 in 2021 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations slumped 342.73% in 2024, then soared 615.46% in 2025.
- Over 5 years, Cash from Operations stood at 95155.0 in 2021, then surged by 49.99% to 47591.0 in 2022, then sank by 322.54% to 201089.0 in 2023, then slumped by 342.73% to 890275.0 in 2024, then grew by 7.54% to 823106.0 in 2025.
- According to Business Quant data, Cash from Operations over the past three periods registered 823106.0, 94907.0, and 49143.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | -823,106.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | -823,106.00 |
| Nov 30, 2025 | -823,106.00 |
| Aug 31, 2025 | -94,907.00 |
| Aug 31, 2025 | -94,907.00 |
| May 31, 2025 | -49,143.00 |
| May 31, 2025 | -49,143.00 |
| Feb 28, 2025 | 709,372.00 |
| Feb 28, 2025 | 709,372.00 |
| Nov 30, 2024 | -890,275.00 |
| Nov 30, 2024 | -890,275.00 |
| Aug 31, 2024 | -148,098.00 |
| Aug 31, 2024 | -148,098.00 |
| May 31, 2024 | -59,530.00 |
| May 31, 2024 | -59,530.00 |
| Feb 29, 2024 | -137,620.00 |
| Feb 29, 2024 | -137,620.00 |
| Nov 30, 2023 | -201,089.00 |
| Nov 30, 2023 | -201,089.00 |
| Aug 31, 2023 | -119,768.00 |
| Aug 31, 2023 | -119,768.00 |